Abvc Biopharma (ABVC) Asset Utilization Ratio (2011 - 2025)
Abvc Biopharma's (ABVC) quarterly Asset Utilization Ratio came in at 0.09 in Q3 2025, up 40.15% on a YoY basis from 0.06 in Q3 2024, and up 35.74% quarter-over-quarter from 0.07 in Q4 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) Asset Utilization Ratio (2011 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has reported Asset Utilization Ratio for 12 consecutive years, with 0.09 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Asset Utilization Ratio rose 40.15% year-over-year to 0.09; the trailing twelve-month figure through Sep 2025 stood at 0.09 (up 40.15% YoY), and the FY2025 full-year result was 0.0, down 96.66% from the prior year.
- Asset Utilization Ratio rose to 0.09 in Q3 2025 per ABVC's latest filing, from 0.07 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.11 in Q1 2023 and bottomed at 0.0 in Q1 2024.
- Historically, Asset Utilization Ratio has averaged 0.05 across 5 years, with a median of 0.05 in 2021.
- The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio surged 1049.65% in 2023, then tumbled 96.95% in 2024.
- Over 5 years, Asset Utilization Ratio stood at 0.03 in 2021, then surged by 253.99% to 0.1 in 2022, then sank by 79.24% to 0.02 in 2023, then soared by 231.4% to 0.07 in 2024, then jumped by 35.74% to 0.09 in 2025.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.09, 0.07, and 0.06 for Q3 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 0.09 |
| Dec 31, 2024 | 0.07 |
| Sep 30, 2024 | 0.06 |
| Jun 30, 2024 | 0.02 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | 0.09 |
| Jun 30, 2023 | 0.08 |
| Mar 31, 2023 | 0.11 |
| Dec 31, 2022 | 0.10 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.03 |
| Mar 31, 2022 | 0.01 |
| Dec 31, 2021 | 0.03 |
| Sep 30, 2021 | 0.04 |
| Jun 30, 2021 | 0.05 |
| Mar 31, 2021 | 0.06 |
| Dec 31, 2020 | 0.05 |
| Sep 30, 2020 | 0.08 |
| Dec 31, 2019 | 0.10 |